

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI911042

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED	03/20/2025
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	THERAKOS DEVELOPMENT LIMITED
<b>Street Address:</b>	c/o TMF Group, Ground Floor, Two Dockland Central
<b>Internal Address:</b>	Guild Street North Dock
<b>City:</b>	Dublin 1
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	D01 K2C5
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15261968
<b>Application Number:</b>	16537103
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	8017995800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8017995800
<b>Email:</b>	lledlacek@hollandhart.com
<b>Correspondent Name:</b>	Loren R. HULSE
<b>Address Line 1:</b>	Holland & Hart LLP
<b>Address Line 2:</b>	222 S. Main Street, Suite 2200
<b>Address Line 4:</b>	Salt Lake City, UTAH 84101
<b>ATTORNEY DOCKET NUMBER:</b>	125264.0002
<b>NAME OF SUBMITTER:</b>	Laura Sedlacek
<b>SIGNATURE:</b>	/Laura Sedlacek/
<b>DATE SIGNED:</b>	03/25/2025
<b>Total Attachments: 2</b>	
source=Confirmatory_Assignment_US15261968_US16537103_MALLINCKRODT_PHARMACEUTICALS_IRELAND_LIM	
source=Confirmatory_Assignment_US15261968_US16537103_MALLINCKRODT_PHARMACEUTICALS_IRELAND_LIM	

HH Ref. 125264.0002 (USSN 15/261,968, 16/537,103)

**CONFIRMATORY ASSIGNMENT**

This Confirmatory Assignment Agreement is entered as of 29 November 2024 (“Effective Date”) between **MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED** (“ASSIGNOR”), a company having a place of business at College Business and Technology Park, Cruiserath Road, Blanchardstown D15 TX2V, Ireland, and **THERAKOS DEVELOPMENT LIMITED**, formerly Solaris IPCo Limited (“ASSIGNEE”), a company having a place of business at c/o TMF Group, Ground Floor, Two Dockland Central, Guild Street North Dock, Dublin 1, D01 K2C5, Ireland.

The ASSIGNOR hereby confirms assignment and transfer unto the ASSIGNEE of all of its right, title, and interest in and to the following patents and patent applications, including the right to damages for past or future infringement, misappropriation or violation thereof:

TITLE	COUNTRY	APPLICATION NO	FILING DATE	PATENT NO	ISSUE DATE
CENTRIFUGE SYSTEM AND METHOD FOR COMPONENT TRACKING	UNITED STATES OF AMERICA	15/261,968	11 September 2016	10,434,239	08 October 2019
CENTRIFUGE SYSTEM AND METHOD FOR COMPONENT TRACKING	UNITED STATES OF AMERICA	16/537,103	09 August 2019	11,020,522	01 June 2021

The ASSIGNOR confirms assignment to the ASSIGNEE of all of its right, title and interest in and to (i) such patents and patent applications, (ii) all other patents and patent applications owned by Assignor that issue from, or otherwise claim priority to, any of the foregoing, and (iii) any foreign counterparts owned by Assignor to any of the foregoing (the “ASSIGNED PATENT RIGHTS”);

The ASSIGNOR authorizes the ASSIGNEE to apply for and receive any and all United States and foreign patents for the ASSIGNED PATENT RIGHTS in its own name;

The ASSIGNOR authorizes and requests the issuing authority to issue any and all United States and foreign patents granted on the ASSIGNED PATENT RIGHTS in the name of the ASSIGNEE;

The undersigned are duly authorized to execute this document on behalf of the ASSIGNOR and the ASSIGNEE.

**HH Ref. 125264.0002 (USSN 15/261,968, 16/537,103)**

**ASSIGNOR:**

Signed on behalf of **MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED**

By: Lars Taavola  
Digitally signed by Lars Taavola  
Date: 2025.03.20 18:55:38  
+04'00'

Execution Date: March 20, 2025

Name Lars Taavola

Title: Vice President, Chief Intellectual Property Counsel

**ASSIGNEE**

Signed on behalf of **THERAKOS DEVELOPMENT LIMITED**, formerly Solaris IPCo

By: Signed by:  
*Michael Rehtiene*  
A9D4D23175464AB...

Execution Date: 3/25/2025

Name Michael Rehtiene

Title: Co-CEO Therakos, LLC